C. D. VenturesI must be losing my mind (I'm sure I am and need apabetalone) but I thought there were posts about CD Ventures being something like the 5th largest shareholder in RVX after Eastern, NGN, Hepalink, Don?, ????? I'll check the latest annual report to see if they are listed.
On Feb 21st on Agora fouremm said that CD Ventures is a German Vencap fund and the managing director is Christoph Boehringer and he is a 4th generation decendant of Albert Boehringer which is now Boehringer Engelheim. He is a billionnaire.
This is something I did not know (along with everything else in the world) and it strikes me as very significant.
If he is in testing the waters at RVX with his VC fund it could also imply that Boehringer Engelheim could be a gateway for apabetalone (and much more) into Europe???
IMHO Eastern, NGN, Hepalink and groups like CD Ventures are not putting thier money in this to see a $10 share price. They are in this investment for billions and to benefit from the many, many business possibilites.
I'm not good at searches but if anyone has insight on this please let us know.
We are still awaiting the next licensing deal announcement so I'll be interested to see if CD Ventures shows up?
There is now such a remarkable flow of discoveries on apabetalone (rvx-208) at this stage and the momentum continues to build rapidly and includes cardiovascular disease (for patients with low HDL - unlike LDL drugs), diabetes melletus, rheumatoid arthritus, chronic kidney disease, muscular dystrophy, retinitis pigmentosis and the exploration of Alzheimers is still on the books. And this is just with 1 of the 1500 (and 7 near in) compounds. Also, who knows where independent academic scientists are going to take epigenetics and BET inhibition as we speak?
Obviously the compounds and biochemical processes are incredibly complex but there is one thing that seems to almost be a common thread throughout the research and it is one of the 6 multi-modal impacts of apabetalone and that is... the reduction of inflammation!
I'm far too optimistic but the build in the scientific progress has me very happy. Epigenetics (the software that controls and can correct rogue protein production by broken genes) is being discovered and rapidly gaining scientific interest throughout the world. Lots of PhDs to be earned on this one.
Now if Dr Wong and Zenith nail it with zen3694 on metastatic castration resistant prostate cancer(mCRPC) either on it's own or with enzalutimide or other standard of care drugs it will hit epigenetics out of the ball park and Pfizer may just take a peek.
What is starting to amaze me is that so far I am not aware of any Canadian based funding for RVX and Zenith and that is the very sad story of Canada. We all know that brilliant ideas are born and develop in Canada but the huge gap in Canada's development is the lack of "take it to market" funding.
GLTA DYODD
Toinv